8-K Announcements
6Material company update
Mar 18, 2026·SEC
Material company update
Dec 18, 2025·SEC
Material company update
Dec 11, 2025·SEC
Ovid Therapeutics Inc.(OVID)Earnings, Financials & Key Ratios
OVID•NASDAQ
$2.73
$355M mkt cap·Price updated May 7, 2026
AboutOvid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Show more
- Revenue$7M+1181.3%
- EBITDA-$42M+31.2%
- Net Income-$17M+34.1%
- EPS (Diluted)-0.24+35.1%
- Gross Margin95.86%-4.1%
- EBITDA Margin-581.07%+94.6%
- Operating Margin-585.2%+94.6%
- Net Margin-240.13%+94.9%
- ROE-17.51%+48.3%
- ROIC-36.25%+47.9%
- Debt/Equity0.01-94.9%
OVID Key Insights
Ovid Therapeutics Inc. (OVID) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 95 (top 5%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 10.5% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OVID Price & Volume
Ovid Therapeutics Inc. (OVID) stock price & volume — 10-year historical chart
Loading chart...
OVID Growth Metrics
Ovid Therapeutics Inc. (OVID) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-10.48%
3 Years68.99%
TTM1181.27%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM34.12%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM32.66%
Return on Capital
10 Years-53.2%
5 Years-13.07%
3 Years-45.95%
Last Year-37.84%
OVID Recent Earnings
Ovid Therapeutics Inc. (OVID) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Mar 18, 2026EPS
$0.06
Est $0.10
+160.0%
Revenue
$718,000
Est $78,250
+817.6%
Q4 2025
Nov 12, 2025EPS
$0.17
Est $0.15
-13.3%
Revenue
$132,000
Est $62,600
+110.9%
Q3 2025
Aug 13, 2025EPS
$0.06
Est $0.16
+62.5%
Revenue
$6M
Est $61,330
+10126.6%
Q2 2025
May 13, 2025EPS
$0.14
Est $0.14
+0.0%
Revenue
$130,000
Est $42,500
+205.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 18, 2026 | $0.06vs $0.10+160.0% | $718,000vs $78,250+817.6% |
| Q4 2025 | Nov 12, 2025 | $0.17vs $0.15-13.3% | $132,000vs $62,600+110.9% |
| Q3 2025 | Aug 13, 2025 | $0.06vs $0.16+62.5% | $6Mvs $61,330+10126.6% |
| Q2 2025 | May 13, 2025 | $0.14vs $0.14+0.0% | $130,000vs $42,500+205.9% |
Based on last 12 quarters of dataView full earnings history →
OVID Peer Comparison
Ovid Therapeutics Inc. (OVID) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 LGND | 4.13B | 210.33 | -956.05 | 27.28% | 19.34% | 5.11% | 0.01 | |
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 PTCT | 5.35B | 64.49 | 8.29 | 114.51% | -22.58% | |||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 ARVN | 651.76M | 10.19 | -7.96 | -0.3% | -30.77% | -14.25% | 0.02 |
Compare OVID vs Peers
Ovid Therapeutics Inc. (OVID) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OVID Income Statement
Ovid Therapeutics Inc. (OVID) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 12.62M | 208.38M | 1.5M | 392K | 566K | 7.25M |
| Revenue Growth % | - | - | - | - | 1551.57% | -99.28% | -73.91% | 44.39% | 1181.27% |
| Cost of Goods Sold | 80.31K | 141.73K | 0 | 0 | 0 | 0 | 0 | 0 | 300K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 4.14% |
| Gross Profit | -80.31K▲ 0% | -142K▼ 76.8% | 0▲ 100.0% | 12.62M▲ 0% | 208.38M▲ 1551.6% | 1.5M▼ 99.3% | 392K▼ 73.9% | 566K▲ 44.4% | 6.95M▲ 1128.3% |
| Gross Margin % | - | - | - | 100% | 100% | 100% | 100% | 100% | 95.86% |
| Gross Profit Growth % | -42.11% | -76.81% | 100% | - | 1551.57% | -99.28% | -73.91% | 44.39% | 1128.27% |
| Operating Expenses | 65.01M | 52.93M | 61.41M | 94.05M | 84.17M | 57.05M | 59.67M | 62.45M | 49.39M |
| OpEx % of Revenue | - | - | - | 745.4% | 40.39% | 3796.44% | 15222.7% | 11033.75% | 681.07% |
| Selling, General & Admin | 15.04M | 19.14M | 19.25M | 30.63M | 37.23M | 32.43M | 29.59M | 25.68M | 24.11M |
| SG&A % of Revenue | - | - | - | 242.77% | 17.87% | 2158.18% | 7547.19% | 4537.63% | 332.45% |
| Research & Development | 49.97M | 33.79M | 46.86M | 64.12M | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M |
| R&D % of Revenue | - | - | - | 508.17% | 22.53% | 1638.23% | 7292.86% | 6495.94% | 352.76% |
| Other Operating Expenses | 0 | 0 | -4.7M | -700K | 1.1K | 510 | 1.5M | 1K | -300K |
| Operating Income | -65.01M▲ 0% | -52.93M▲ 18.6% | -61.41M▼ 16.0% | -81.43M▼ 32.6% | 124.21M▲ 252.5% | -55.55M▼ 144.7% | -59.28M▼ 6.7% | -61.88M▼ 4.4% | -42.44M▲ 31.4% |
| Operating Margin % | - | - | - | -645.4% | 59.61% | -3696.44% | -15122.7% | -10933.75% | -585.2% |
| Operating Income Growth % | -188.48% | 18.58% | -16.02% | -32.6% | 252.53% | -144.72% | -6.72% | -4.39% | 31.42% |
| EBITDA | -64.93M | -52.79M | -61.15M | -81.12M | 124.45M | -54.17M | -58.71M | -61.27M | -42.14M |
| EBITDA Margin % | - | - | - | -642.96% | 59.72% | -3604.5% | -14977.81% | -10825.44% | -581.07% |
| EBITDA Growth % | -188.84% | 18.69% | -15.84% | -32.65% | 253.4% | -143.53% | -8.39% | -4.36% | 31.23% |
| D&A (Non-Cash Add-back) | 80.31K | 141.73K | 255K | 306.85K | 237.08K | 1.38M | 568K | 613K | 300K |
| EBIT | -64.81M | -52.93M | -61.41M | -81.43M | 124.21M | -55.55M | -57.58M | -58.38M | -42.44M |
| Net Interest Income | 0 | 0 | 948.22K | 395.4K | 0 | 0 | 4.9M | 3.9M | 0 |
| Interest Income | 201.51K | 952.07K | 948.22K | 395.4K | 0 | 0 | 4.9M | 3.9M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 201.51K | 952.07K | 948.22K | 395.4K | -45.69K | 1.38M | 6.94M | 35.45M | 0 |
| Pretax Income | -64.81M▲ 0% | -51.98M▲ 19.8% | -60.46M▼ 16.3% | -81.04M▼ 34.0% | 124.16M▲ 253.2% | -54.17M▼ 143.6% | -52.34M▲ 3.4% | -26.43M▲ 49.5% | -17.41M▲ 34.1% |
| Pretax Margin % | - | - | - | -642.26% | 59.58% | -3604.66% | -13351.79% | -4670.14% | -240.13% |
| Income Tax | -80.31K | 0 | 0 | 0 | 1.33M | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.12% | 0% | 0% | 0% | 1.07% | 0% | 0% | 0% | 0% |
| Net Income | -64.81M▲ 0% | -51.98M▲ 19.8% | -60.46M▼ 16.3% | -81.04M▼ 34.0% | 122.83M▲ 251.6% | -54.17M▼ 144.1% | -52.34M▲ 3.4% | -26.43M▲ 49.5% | -17.41M▲ 34.1% |
| Net Margin % | - | - | - | -642.26% | 58.95% | -3604.66% | -13351.79% | -4670.14% | -240.13% |
| Net Income Growth % | -189.13% | 19.79% | -16.32% | -34.03% | 251.58% | -144.1% | 3.38% | 49.5% | 34.12% |
| Net Income (Continuing) | -64.81M | -51.98M | -60.46M | -81.04M | 122.83M | -54.17M | -52.34M | -26.43M | -17.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.35▲ 0% | -2.11▲ 37.0% | -1.51▲ 28.4% | -1.39▲ 7.9% | 1.76▲ 226.6% | -0.77▼ 143.8% | -0.74▲ 3.9% | -0.37▲ 50.0% | -0.24▲ 35.1% |
| EPS Growth % | -193.86% | 37.01% | 28.44% | 7.95% | 226.62% | -143.75% | 3.9% | 50% | 35.14% |
| EPS (Basic) | -3.35 | -2.11 | -1.51 | -1.39 | 1.78 | -0.77 | -0.74 | -0.37 | -0.24 |
| Diluted Shares Outstanding | 19.34M | 24.63M | 39.22M | 58.45M | 68.07M | 70.42M | 70.58M | 70.91M | 73.74M |
| Basic Shares Outstanding | 19.34M | 24.63M | 39.22M | 58.45M | 67.48M | 70.42M | 70.58M | 70.91M | 73.74M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
OVID Balance Sheet
Ovid Therapeutics Inc. (OVID) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 88.59M | 44.27M | 79.81M | 74.84M | 190.48M | 131.38M | 109.6M | 55.94M | 90.45M |
| Cash & Short-Term Investments | 87.13M | 41.5M | 76.74M | 72.03M | 187.8M | 129M | 105.83M | 53.08M | 90.45M |
| Cash Only | 87.13M | 36.49M | 41.9M | 72.03M | 187.8M | 44.87M | 27.04M | 26.3M | 13.15M |
| Short-Term Investments | 0 | 5.01M | 34.84M | 0 | 0 | 84.13M | 78.79M | 26.77M | 56.48M |
| Accounts Receivable | 0 | 0 | 1.13M | 141.76K | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | 4.1 | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 600.1K | 0 | 0 | 2.68M | 1 | 1K | 0 | 0 |
| Total Non-Current Assets | 869.55K | 3.38M | 1.03M | 1.08M | 4.07M | 23.89M | 34.43M | 36.23M | 60.49M |
| Property, Plant & Equipment | 51.77K | 69.87K | 68.36K | 135.62K | 242.76K | 16.07M | 14.66M | 13.23M | 0 |
| Fixed Asset Turnover | - | - | - | 93.03x | 858.40x | 0.09x | 0.03x | 0.04x | - |
| Goodwill | 0 | 0 | -247 | 100 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 124.19K | 391.87K | 467.25K | 318.9K | 164K | 222.1K | 200K | 92K | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 3.56M | 5.62M | 17.63M | 20.97M | 0 |
| Other Non-Current Assets | 693.59K | 2.92M | 495.18K | 627.8K | 96.13K | 1.97M | 1.94M | 1.93M | 60.49M |
| Total Assets | 89.46M▲ 0% | 47.65M▼ 46.7% | 80.84M▲ 69.7% | 75.93M▼ 6.1% | 194.54M▲ 156.2% | 155.27M▼ 20.2% | 144.03M▼ 7.2% | 92.17M▼ 36.0% | 150.93M▲ 63.8% |
| Asset Turnover | - | - | - | 0.17x | 1.07x | 0.01x | 0.00x | 0.01x | 0.05x |
| Asset Growth % | 68.7% | -46.73% | 69.66% | -6.08% | 156.23% | -20.19% | -7.24% | -36.01% | 63.76% |
| Total Current Liabilities | 6.02M | 8.84M | 10.53M | 22.06M | 14.8M | 6.99M | 11.47M | 10.52M | 8.29M |
| Accounts Payable | 2.03M | 3.76M | 3.26M | 5.45M | 7.13M | 1.95M | 3.7M | 3.19M | 1.96M |
| Days Payables Outstanding | 9.21K | 9.67K | - | - | - | - | - | - | 2.38K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.43M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 2.21M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.08M | 2.31M | 4.55M | 8.19M | 3.91M | 0 | 0 | 1K | 4.9M |
| Current Ratio | 14.71x | 5.01x | 7.58x | 3.39x | 12.87x | 18.79x | 9.55x | 5.32x | 10.91x |
| Quick Ratio | 14.71x | 5.01x | 7.58x | 3.39x | 12.87x | 18.79x | 9.55x | 5.32x | 10.91x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 286.56K | 10.23M | 0 | 16M | 44.76M | 13.42M | 11.99M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 16M | 14.76M | 13.42M | 11.99M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 286.56K | 61.2K | 0 | 1 | 30M | 0 | 0 |
| Total Liabilities | 6.02M | 8.84M | 10.82M | 32.29M | 14.8M | 22.99M | 56.23M | 23.94M | 20.27M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 16.54M | 16M | 14.76M | 1.43M |
| Net Debt | -87.13M | -36.49M | -41.9M | -72.03M | -187.8M | -28.33M | -11.04M | -11.55M | -11.72M |
| Debt / Equity | - | - | - | - | - | 0.13x | 0.18x | 0.22x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | -1.51x | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 83.44M▲ 0% | 38.81M▼ 53.5% | 70.02M▲ 80.4% | 43.63M▼ 37.7% | 179.75M▲ 312.0% | 132.27M▼ 26.4% | 87.8M▼ 33.6% | 68.23M▼ 22.3% | 130.66M▲ 91.5% |
| Equity Growth % | 69.26% | -53.49% | 80.45% | -37.69% | 311.96% | -26.41% | -33.62% | -22.29% | 91.51% |
| Book Value per Share | 4.31 | 1.58 | 1.79 | 0.75 | 2.64 | 1.88 | 1.24 | 0.96 | 1.77 |
| Total Shareholders' Equity | 83.44M | 38.81M | 70.02M | 43.63M | 179.75M | 132.27M | 87.8M | 68.23M | 130.66M |
| Common Stock | 24.61K | 24.65K | 54.71K | 65.74K | 70.36K | 70.47K | 71K | 71K | 130K |
| Retained Earnings | -100.72M | -152.7M | -213.16M | -294.19M | -171.36M | -225.53M | -277.87M | -304.3M | -321.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -50.91K | -1.83K | 2.47K | 0 | 0 | -42.19K | 0 | -35K | -202K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OVID Cash Flow Statement
Ovid Therapeutics Inc. (OVID) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -31.47M | -45.56M | -51.09M | -51.58M | 118.61M | -55.23M | -45.78M | -55.96M | -38.33M |
| Operating CF Margin % | - | - | - | -408.84% | 56.92% | -3675.08% | -11678.81% | -9886.22% | -528.6% |
| Operating CF Growth % | -76.78% | -44.77% | -12.14% | -0.97% | 329.94% | -146.56% | 17.1% | -22.23% | 31.49% |
| Net Income | -64.81M | -51.98M | -60.46M | -81.04M | 119.84M | -54.17M | -52.34M | -26.43M | -17.41M |
| Depreciation & Amortization | 80.31K | 141.73K | 255K | 306.85K | 237K | 1.38M | 1.6M | 613K | 273K |
| Stock-Based Compensation | 6.4M | 7.06M | 5.21M | 7.53M | 0 | 6.56M | 7.29M | 6.28M | 4.81M |
| Deferred Taxes | 0 | 4.61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 25.86M | -1.24K | -29.63K | -199.41K | 15.35M | -764.94K | -4.71M | -36.26M | -21.9M |
| Working Capital Changes | 996.85K | -787.91K | 3.94M | 21.82M | -16.81M | -8.23M | 2.39M | -150K | -4.1M |
| Change in Receivables | 7.37K | 0 | -531.04K | 989.38K | 141.76K | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.08M | 1.65M | -653.95K | 2.33M | 1.7M | -5.17M | 1.75M | -512K | -1.23M |
| Cash from Investing | -47.39K | -5.36M | -30.04M | 34.65M | -1.82M | -87.88M | -2.58M | 54.59M | -49.85M |
| Capital Expenditures | -47.39K | -352.02K | -57.16K | -127.24K | -189.41K | -1.42M | -40.31K | -71K | 0 |
| CapEx % of Revenue | - | - | - | 1.01% | 0.09% | 94.41% | 10.28% | 12.54% | - |
| Acquisitions | 0 | 318.15K | 0 | 0 | 0 | -2.5M | -10M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -8.48K | -318.15K | -186.89K | -263.44K | 0 | -1M | -97.15K | -89K | 0 |
| Cash from Financing | 66.7M | 286.14K | 86.54M | 47.07M | 904.08K | 180.66K | 30.54M | 622K | 75.21M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 30M | 0 | 0 |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 925.4K | 180.66K | 535.2K | 622K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -3.05M | 286.14K | 131.9K | 341.04K | -21.31K | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.19M▲ 0% | -50.64M▼ 243.9% | 5.41M▲ 110.7% | 30.14M▲ 457.3% | 115.76M▲ 284.1% | -142.93M▼ 223.5% | -17.83M▲ 87.5% | -740K▲ 95.8% | -13.15M▼ 1676.8% |
| Free Cash Flow | -31.52M▲ 0% | -45.91M▼ 45.7% | -51.33M▼ 11.8% | -51.97M▼ 1.2% | 118.43M▲ 327.9% | -56.65M▼ 147.8% | -45.92M▲ 18.9% | -56.03M▼ 22.0% | -38.33M▲ 31.6% |
| FCF Margin % | - | - | - | -411.93% | 56.83% | -3769.49% | -11713.87% | -9898.76% | -528.6% |
| FCF Growth % | -75.18% | -45.67% | -11.81% | -1.25% | 327.86% | -147.83% | 18.94% | -22.01% | 31.58% |
| FCF per Share | -1.63 | -1.86 | -1.31 | -0.89 | 1.74 | -0.80 | -0.65 | -0.79 | -0.52 |
| FCF Conversion (FCF/Net Income) | 0.49x | 0.88x | 0.85x | 0.64x | 0.97x | 1.02x | 0.87x | 2.12x | 2.20x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OVID Key Ratios
Ovid Therapeutics Inc. (OVID) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -38.2% | -97.65% | -85.04% | -111.11% | -142.6% | 109.98% | -34.72% | -47.57% | -33.88% | -17.51% |
| Return on Invested Capital (ROIC) | - | - | - | -302.59% | - | - | -86.89% | -49.21% | -69.57% | -36.25% |
| Gross Margin | - | - | - | - | 100% | 100% | 100% | 100% | 100% | 95.86% |
| Net Margin | - | - | - | - | -642.26% | 58.95% | -3604.66% | -13351.79% | -4670.14% | -240.13% |
| Debt / Equity | - | - | - | - | - | - | 0.13x | 0.18x | 0.22x | 0.01x |
| FCF Conversion | 0.79x | 0.49x | 0.88x | 0.85x | 0.64x | 0.97x | 1.02x | 0.87x | 2.12x | 2.20x |
| Revenue Growth | - | - | - | - | - | 1551.57% | -99.28% | -73.91% | 44.39% | 1181.27% |
OVID SEC Filings & Documents
Ovid Therapeutics Inc. (OVID) SEC filings — annual & quarterly reports (10-K, 10-Q)
OVID Frequently Asked Questions
Ovid Therapeutics Inc. (OVID) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ovid Therapeutics Inc. (OVID) reported $7.3M in revenue for fiscal year 2025.
Ovid Therapeutics Inc. (OVID) grew revenue by 1181.3% over the past year. This is strong growth.
Ovid Therapeutics Inc. (OVID) reported a net loss of $17.4M for fiscal year 2025.
Dividend & Returns
Ovid Therapeutics Inc. (OVID) has a return on equity (ROE) of -17.5%. Negative ROE indicates the company is unprofitable.
Ovid Therapeutics Inc. (OVID) had negative free cash flow of $38.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More OVID
Ovid Therapeutics Inc. (OVID) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates